AOD-9604 dosage chart
2 mg Vial
AOD-9604 is dosed at 300 mcg–500 mcg daily via subcutaneous injection in educational protocols. A 2 mg vial reconstituted with bacteriostatic water yields about 0.667 mg/mL. This information is for research and educational use only.
- Reconstitute
- Add 3.0 mL bacteriostatic water → ~0.667 mg/mL (667 mcg/mL) concentration.
- Typical daily range
- 300–500 mcg once daily (gradual titration).
- Easy measuring
- At 0.667 mg/mL, 1 unit = 0.01 mL ≈ 6.67 mcg on a U‑100 insulin syringe.
- Storage
- Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Dosing schedule
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 300 mcg | 45 units (0.45 mL) |
| Weeks 5–12 | 500 mcg | 75 units (0.75 mL) |
Reconstitution steps
- 1Draw 3.0 mL bacteriostatic water with a sterile syringe.
- 2Inject slowly down the vial wall; avoid foaming.
- 3Gently swirl/roll until dissolved (do not shake).
- 4Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes (U‑100, 29–31 gauge); dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and prevent lipohypertrophy.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Each 2 mg vial provides approximately 4 days of dosing at 500 mcg/day or 6–7 days at 300 mcg/day.
How This Works
AOD‑9604 is a modified C‑terminal fragment of human growth hormone that retains the lipolytic (fat‑reducing) domain without the growth‑promoting effects. It binds to adipose tissue and triggers breakdown of stored fat while blocking new fat storage (re‑esterification) in adipocytes. At the molecular level, chronic AOD‑9604 administration upregulates β3‑adrenergic receptors in fat tissue, reversing obesity‑related suppression of these fat‑burning receptors. Unlike full‑length hGH, AOD‑9604 does not meaningfully elevate IGF‑1 levels or worsen glucose tolerance, making its tolerability indistinguishable from placebo in human trials.
Potential Benefits & Side Effects
Observations from preclinical and clinical literature.
- Supports reductions in fat mass and increases in fat oxidation over time; clinical trials showed modest but statistically significant weight loss (approximately 2.6 kg vs. 0.8 kg placebo over 12 weeks at 1 mg/day).
- Preferential loss of abdominal fat observed, resembling the pattern seen with low‑dose hGH therapy.
- Does not meaningfully raise IGF‑1 and shows a placebo‑like safety profile in human studies; no anti‑AOD9604 antibodies detected.
- Emerging regenerative potential: preclinical studies suggest possible cartilage repair and bone health benefits.
- Generally well tolerated; occasional mild injection‑site reactions (redness/itch) may occur with subcutaneous administration.
Lifestyle Factors
Complementary strategies for best outcomes.
- Pair with a hypocaloric, protein‑forward diet tailored to energy needs; AOD‑9604 is best viewed as a supportive aid to fat loss rather than a stand‑alone solution.
- Combine resistance training and aerobic activity to reinforce metabolic adaptations.
- Prioritize sleep and stress management to support adherence and recovery.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources.
- Clean the vial stopper and skin with alcohol; allow to dry completely.
- Pinch a skinfold; insert the needle at 90° (or 45° if very little subcutaneous fat) into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen at least 2 inches from navel, thighs, upper arms) to avoid lipohypertrophy.
important-note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
AOD-9604 dosage FAQs
How much bacteriostatic water do you use to reconstitute AOD-9604?
Add 3.0 mL bacteriostatic water → ~0.667 mg/mL (667 mcg/mL) concentration. for a 2 mg Vial vial. Add the water slowly against the inside wall of the vial and swirl — never shake — until the powder fully dissolves.
What does the AOD-9604 dosing schedule look like?
Weeks 1–4 — 300 mcg — 45 units (0.45 mL); Weeks 5–12 — 500 mcg — 75 units (0.75 mL). The full table above lists every step with matching syringe units.
What are the mixing steps for AOD-9604?
Draw 3.0 mL bacteriostatic water with a sterile syringe. Inject slowly down the vial wall; avoid foaming. Gently swirl/roll until dissolved (do not shake).
How should reconstituted AOD-9604 be stored?
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles..
How many insulin syringe units equal a AOD-9604 dose?
Units depend on the water volume you used. Divide your target dose by the vial concentration to get millilitres, then multiply by 100 — 1 unit on a U-100 insulin syringe is 0.01 mL. The Spartan Peptides reconstitution calculator does this conversion for you.
Is AOD-9604 approved for human use?
No. AOD-9604 is sold and referenced strictly as a research chemical. Nothing on this page is medical advice and the material is not for human consumption.
Educational and research information only. Not medical advice, not for human consumption. Values are reference figures — always verify your own math with the reconstitution calculator.
On any insulin syringe, 1 unit = 0.01 mL, so unit counts above hold across brands.